Latest news and press releases about Palvella Therapeutics, Inc. (PVLA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Price
| Price | $151.43 |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 42.11 |
| EV / EBITDA | -31.21 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -149.07% |
| Return on Invested Capital | -79.73% |
| Return on Assets | -70.04% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABUS · EYPT · GHRS · KURA · NBTX · PROK · RZLT
Explore sector: Healthcare · Biotechnology
More sections of PVLA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks